Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.
Katsutsugu UmedaTakako MiyamuraKenji YamadaHideki SanoAko HosonoMinako SumiHajime OkitaTadashi KumamotoAkira KawaiJunya HirayamaRyoji JyokoAkihisa SawadaHideki NakayamaYosuke HosoyaNaoko MaedaNobuyuki YamamotoChihaya ImaiDaiichiro HasegawaMotoaki ChinToshifumi Ozakinull nullPublished in: Cancer reports (Hoboken, N.J.) (2021)
The present study fails to demonstrate significant clinical benefit of SCT for recurrent or refractory localized ESFT. Recently established chemotherapy regimens may increase the survival rate of patients with recurrent or refractory localized ESFT while attenuating the beneficial effect of SCT.
Keyphrases